請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21897
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡幸真(Hsing-Chen Tsai) | |
dc.contributor.author | Yi-Chieh Wu | en |
dc.contributor.author | 吳怡潔 | zh_TW |
dc.date.accessioned | 2021-06-08T03:52:01Z | - |
dc.date.copyright | 2018-08-30 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-20 | |
dc.identifier.citation | 1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7–30 (2018).
2. Lung Cancer Symptoms, Signs, Stages, Treatment & Types. MedicineNet Available at: https://www.medicinenet.com/lung_cancer/article.htm. (Accessed: 21st May 2018) 3. Lung Cancer: Stages, Survival Rates, and More. Healthline (2016). Available at: https://www.healthline.com/health/lung-cancer-stages-survival-rates. (Accessed: 16th June 2018) 4. Carter, B. W., Halpenny, D. F., Ginsberg, M. S., Papadimitrakopoulou, V. A. & de Groot, P. M. Immunotherapy in Non–Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. J. Thorac. Imaging 32, 300–312 (2017). 5. Crespo, J., Sun, H., Welling, T. H., Tian, Z. & Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25, 214–221 (2013). 6. The tumor microenvironment at a glance | Journal of Cell Science. Available at: http://jcs.biologists.org/content/125/23/5591.long. (Accessed: 12th July 2018) 7. Beatty, G. L. & Gladney, W. L. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clin. Cancer Res. 21, 687–692 (2015). 8. Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011). 9. Kahan, S. M., Wherry, E. J. & Zajac, A. J. T Cell Exhaustion During Persistent Viral Infections. Virology 0, 180–193 (2015). 10. Davoodzadeh Gholami, M. et al. Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. Cell. Immunol. 322, 1–14 (2017). 11. Catakovic, K., Klieser, E., Neureiter, D. & Geisberger, R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun. Signal. CCS 15, (2017). 12. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. Cancer Cell 33, 547–562 (2018). 13. Thommen, D. S. et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol. Res. 3, 1344–1355 (2015). 14. Zhang, Y., Huang, S., Gong, D., Qin, Y. & Shen, Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 7, 389–395 (2010). 15. Tsai, H.-F. & Hsu, P.-N. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. J. Biomed. Sci. 24, 35 (2017). 16. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. http://dx.doi.org/10.1056/NEJMoa1003466 (2010). doi:10.1056/NEJMoa1003466 17. Malhotra, J., Jabbour, S. K. & Aisner, J. Current state of immunotherapy for non-small cell lung cancer. Transl. Lung Cancer Res. 6, 196–211 (2017). 18. Johnson, D. B., Rioth, M. J. & Horn, L. Immune Checkpoint Inhibitors in NSCLC. Curr. Treat. Options Oncol. 15, 658–669 (2014). 19. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015). 20. Ribas, A. et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 315, 1600–1609 (2016). 21. Utzschneider, D. T. et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14, 603–610 (2013). 22. Ahn, E. et al. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J. Virol. 90, 8934–8946 (2016). 23. Dupont, C., Armant, D. R. & Brenner, C. A. Epigenetics: Definition, Mechanisms and Clinical Perspective. Semin. Reprod. Med. 27, 351–357 (2009). 24. Sarkar, S., Goldgar, S., Byler, S., Rosenthal, S. & Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5, 87–94 (2013). 25. Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016). 26. Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165–1169 (2016). 27. Mognol, G. P. et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc. Natl. Acad. Sci. 114, E2776–E2785 (2017). 28. Philip, M. et al. Chromatin states define tumor-specific T cell dysfunction and reprogramming. Nature 545, 452–456 (2017). 29. Ghoneim, H. E. et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 170, 142-157.e19 (2017). 30. Terranova-Barberio, M., Thomas, S. & Munster, P. N. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 8, 705–719 (2016). 31. Gallagher, S. J., Shklovskaya, E. & Hersey, P. Epigenetic modulation in cancer immunotherapy. Curr. Opin. Pharmacol. 35, 48–56 (2017). 32. Dunn, J. & Rao, S. Epigenetics and immunotherapy: The current state of play. Mol. Immunol. 87, 227–239 (2017). 33. What is Pleural Effusion? Treatment, Causes & Symptoms. MedicineNet Available at: https://www.medicinenet.com/pleural_effusion_fluid_in_the_chest_or_on_lung/article.htm. (Accessed: 30th May 2018) 34. Atanackovic, D. et al. Characterization of Effusion-Infiltrating T Cells. Clin. Cancer Res. 10, 2600–2608 (2004). 35. Prado-Garcia, H., Aguilar-Cazares, D., Flores-Vergara, H., Mandoki, J. J. & Lopez-Gonzalez, J. S. Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 47, 361–371 (2005). 36. Scherpereel, A. et al. Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer 13, 324 (2013). 37. Li, L. et al. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages. Int. J. Cancer 139, 2261–2269 (2016). 38. Kim, Y. et al. Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. Anticancer Res. 29, 1817–1822 (2009). 39. Kisselbach, L., Merges, M., Bossie, A. & Boyd, A. CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. Cytotechnology 59, 31–44 (2009). 40. Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015). 41. Schietinger, A. et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity 45, 389–401 (2016). 42. Yang, X. et al. Prognostic significance of CD4/CD8 ratio in patients with breast cancer. 7 43. Jackute, J. et al. The prognostic influence of tumor infiltrating Foxp3+CD4+, CD4+ and CD8+ T cells in resected non-small cell lung cancer. J. Inflamm. Lond. Engl. 12, (2015). 44. Zeng, D.-Q. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget 7, 13765–13781 (2016). 45. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010). 46. Mazzone, R., Zwergel, C., Mai, A. & Valente, S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin. Epigenetics 9, 59 (2017). 47. Koeberle, A., Northoff, H. & Werz, O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. Biochem. Pharmacol. 77, 1513–1521 (2009). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21897 | - |
dc.description.abstract | 肺癌在全球的癌症死亡率排名第一,有40%的肺癌患者於診斷時已是晚期階段,導致治療效果有限,因此發展新的治療方式是當前研究的一大重點。近年來癌症免疫療法的研究,為晚期肺癌患者帶來一線曙光。癌細胞利用免疫檢查點(immune checkpoint)的機制抑制腫瘤微環境中的T細胞活性,使T細胞功能減弱或喪失,因而無法有效的清除癌細胞,稱之為T細胞耗竭(T cell exhaustion)。目前針對肺癌的免疫療法,即是通過免疫檢查點抑制劑(immune checkpoint inhibitor)如anti-PD-1和anti-PD-L1單株抗體,重新活化對抗腫瘤的T細胞,使其恢復對癌細胞之毒殺作用。然而,臨床結果顯示只有少部分的肺癌患者對免疫檢查點抑制劑療法有良好反應,且免疫檢查點抑制劑只能短暫恢復T細胞功能,並無法全面持久地改變T細胞的耗竭狀態。目前研究已知,表觀遺傳(epigenetic)調控在T細胞耗竭中扮演重要角色,耗竭性T細胞其基因上的修飾及染色質的構造不同於功能性T細胞,其中耗竭性T細胞相關基因的DNA甲基化也限制了免疫檢查點抑制劑的療效。因此本研究希望能探討表觀遺傳治療對於肺癌中腫瘤反應T細胞的免疫調節作用。
我們自肺癌患者的腫瘤組織與惡性胸水(malignant pleural effusion, MPE)中分離出初代T細胞和肺癌細胞,建立自體腫瘤免疫模型(autologous model),以及系統性地利用流式細胞儀評估腫瘤及惡性胸水中T細胞之表型,並觀察T細胞在表觀遺傳藥物處理後,是否可造成功能性的改變。結果顯示,惡性胸水中有大量T細胞,相較於健康受試者的血液,惡性胸水中T細胞的免疫檢查點有較高表現,呈現耗竭性T細胞的特性。經由DNA去甲基化藥物decitabine(DAC)處理後,發現10nM DAC具有較低的細胞毒性且明顯地提升T細胞的多功能性(T cell polyfunctionality),我們深入探討DAC對於T細胞中PD-1+和PD-1-亞群之影響,發現PD-1+亞群之多功能性T細胞較易受到DAC提升,其中干擾素-γ(IFN-γ)為主要增加的細胞激素。另外,我們利用高通量表觀遺傳藥物篩選平台(epigenetic drug library),初步發現幾種組蛋白修飾的抑制劑藥物會影響T細胞的多功能性,如PCI 34051、Scriptaid、Suberohydroxamic Acid等。 本研究探討肺癌患者的惡性胸水中T細胞特性,並了解DAC對肺癌中的PD-1+ T細胞亞群具有較佳之免疫調節作用,此外,也藉由表觀遺傳藥物篩選平台找出其他可能恢復或提升T細胞功能的藥物,為將來的臨床應用奠定基礎。未來我們將會分析更多樣本中的腫瘤反應T細胞經表觀遺傳藥物處理後的功能性變化,並透過惡性胸水中抽取出的初代細胞,所建立的autologous model,進行T細胞對癌細胞的毒殺分析(immune cell killing assay)。 | zh_TW |
dc.description.abstract | Lung cancer is the leading cause of cancer death worldwide. Nearly 40 % of people with lung cancer were diagnosed at later stages, which results in limited therapeutic options and poor prognosis. Therefore, development of new treatment for lung cancer is very important. In the tumor microenvironment (TME), cancer cells evade immune responses by expressing immune checkpoint to inhibit effector functions of tumor infiltrating lymphocytes (TILs). These functionally impaired T cells were known as exhausted T cells. Currently, immune checkpoint blockade therapy, such as anti-PD-1 and anti-PD-L1, has demonstrated promising responses in advanced lung cancer patients through reinvigorating dysfunctional tumor-reactive T cells. Nevertheless, many patients still do not have favorable responses to this therapy. Besides, T cell rejuvenation may be transient. Recent evidence has suggested that epigenetic regulation plays an important role in T cell exhaustion. Several reports demonstrated that dysfunctional T cells display specific alterations in chromatin accessibility. Dysfunctional T cells also acquire abnormal DNA methylation during tumor development, which restricts the ability of exhausted T cells to respond to PD-1 blockade therapy. Therefore, we aim to investigate immunomodulatory effects of epigenetic therapy on tumor-reactive T cells in lung cancer. In this study, we isolated T cells and lung cancer cells from malignant pleural effusion (MPE) or tumor tissues of lung cancer patients to establish an autologous model of tumor and tumor-reactive lymphocytes. We utilized flow cytometry to characterize the phenotype of T cells from MPE or tumor tissues. We evaluated the effects of decitabine (DAC), a DNA methyltransferase inhibitor, on T cell polyfunctionality. We discovered that T cells in MPE had higher expression of inhibitory immune checkpoints that represent the exhausted phenotype. We also found that PD-1+ T cell subpopulation tended to be more responsive to 10nM DAC in terms of augmentation of polyfunctinality. Among these effector cytokines, IFN-γ is the major functional marker increased by DAC. Furthermore, we utilized epigenetic drug library screening to identify potential drugs that may enhance T cell polyfunctionality. We found some histone modification-targeting drugs that could enhance T cell polyfunctionality, such as PCI 34051、Scriptaid、Suberohydroxamic Acid. Collectively, we characterized the immunophenotypes of tumor reactive T cell in MPE, and the effect of DNA demethylating agents, DAC, on T cell polyfunctionality. In addition, we identified other epigenetic drugs that could potentially be used for modulating T cell functions. In the future, we will study more patient samples to comprehensively investigate the association between epigenetic regulation and tumor-reactive T cells in lung cancer. Furthermore, we will conduct immune cell killing assays using the autologous model we established from MPE to further validate the effects of epigenetic drugs on direct T cell cytotoxicity. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:52:01Z (GMT). No. of bitstreams: 1 ntu-107-R05447001-1.pdf: 2535716 bytes, checksum: 54d9033698b0e4a632e6d2731bbe01c6 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 序言及謝辭 i
中文摘要 ii Abstract iv Contents vi List of Figures. viii List of Tables ix List of Abbreviations x 1. Introduction 1 1.1. Lung cancer 1 1.2. Exhaustion of T cells in cancer 2 1.3. Immune checkpoint blockade therapy in lung cancer 4 1.4. Epigenetic regulation in T cell exhaustion 5 1.5. Combination of epigenetic therapy and immune checkpoint blockade therapy.. 8 1.6. T cells in malignant pleural effusion 9 1.7. Rationale and significance for the study 9 2. Materials and Methods 11 2.1. Study samples 11 2.2. Malignant pleural effusions (MPE) processing 11 2.3. Cryopreservation of lymphocytes 12 2.4. Primary cultures of lung cancer cells from malignant pleural effusions (MPE) 12 2.5. Ex vivo expansion of T cells from MPE 13 2.6. Processing of blood samples 14 2.7. Inhibitory receptors expression of T cells from pleural effusion or blood samples 15 2.8. Decitabine (DAC) treatment on T cells 16 2.9. Stimulation of PBMC or T cells and intracellular cytokine staining 16 2.10.T cell polyfunctionality analyses 17 2.11.Epigenetic drug screening 18 2.12.Statistical analysis 18 3. Results 19 3.1. Establish an in vitro autologous model of tumor-reactive T cells and lung cancer cells from malignant pleural effusion (MPE) 19 3.2. CD4+ T cells are the main population in MPE 19 3.3. Higher IRs expression in T cells from MPE and TIL of lung cancer patients 20 3.4. DAC at 10nM significantly enhance T cell polyfunctionality 21 3.5. PD-1+ T cell subpopulation tended to be more responsive to 10nM DAC in terms of polyfunctinality augmentation 22 3.6. Drugs targeting histone modifications could enhance T cell polyfuncitonality 23 4. Discussion 25 5. Conclusion 29 6. References 30 7. Figures 35 8. Tables 59 | |
dc.language.iso | en | |
dc.title | 探討表觀遺傳治療對肺癌中腫瘤反應T細胞的免疫調節作用 | zh_TW |
dc.title | Immunomodulatory Effects of Epigenetic Therapy on Tumor Reactive T Cells in Lung Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 邱彥霖(Yen-Ling Chiu),張永祺(Yung-Chiy Chang) | |
dc.subject.keyword | 肺癌,癌症免疫治療,表觀遺傳,T細胞,惡性胸水, | zh_TW |
dc.subject.keyword | Lung cancer,Immunotherapy,Epigenetics,T cell,Malignant pleural effusion, | en |
dc.relation.page | 61 | |
dc.identifier.doi | 10.6342/NTU201803261 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.48 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。